Cancer Family
B-Cell Malignant Neoplasm
CI-CAN-00000070Explore in graph →
Hematologic2,083 active trials46 approved drugs301 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000070Explore in graph →
Clinical trials
7,465 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05575973 | Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma | unknown | Phase 2 | 55 | Jianfeng ZhouOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05559450 | Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL | unknown | Phase 2 | 80 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05549284 | Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)(RMO) | unknown | Phase 2 | 36 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT03280160 | Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab | unknown | Phase 2 | 84 | PETHEMA FoundationOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT03891355 | Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL(FIL_KLIMT) | unknown | Phase 2 | 16 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT04277845 | Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma(KMM1910) | unknown | Phase 2 | 49 | Samsung Medical CenterOTHER | 1 | Sep 9, 2022 | clinicaltrials |
| NCT03336073 | Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma | unknown | Phase 2 | 199 | PETHEMA FoundationOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT05466175 | A Study of Olverembatinib in the Treatment of Ph+ ALL | unknown | Phase 2 | 55 | Chen SuningOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05509374 | Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone(KMM2002) | unknown | Phase 2 | 33 | Samsung Medical CenterOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT05509530 | Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM) | unknown | Phase 2 | 30 | Xuzhou Medical UniversityOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT05498636 | SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression | unknown | Phase 1 / Phase 2 | 67 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05504603 | Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma | unknown | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT05497102 | Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT(KMM1911) | unknown | Phase 2 | 58 | Samsung Medical CenterOTHER | 1 | Aug 12, 2022 | clinicaltrials |
| NCT04935580 | Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients | unknown | Phase 1 / Phase 2 | 20 | Shanghai Changzheng HospitalOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT03226301 | A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations | unknown | Phase 2 | 230 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 6 | Aug 2, 2022 | clinicaltrials |
| NCT03736616 | Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL | unknown | Phase 2 | 47 | Swedish Medical CenterOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT05381506 | Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma(O-Gemox) | unknown | Phase 2 | 77 | Sun Yat-sen UniversityOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT03493217 | A Study to Evaluate ICP-022 in Patients With CLL/ SLL | unknown | Phase 1 / Phase 2 | 100 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05436223 | Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma | unknown | Phase 2 | 100 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Jul 5, 2022 | clinicaltrials |
| NCT05428670 | The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma. | unknown | Phase 2 | 150 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT05425654 | RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL | unknown | Phase 2 | 30 | National Research Center for Hematology, RussiaNETWORK | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04831658 | A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Mingzhi ZhangOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05385263 | Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion | unknown | Phase 2 | 20 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | May 26, 2022 | clinicaltrials |
| NCT05390749 | Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL | unknown | Phase 2 | 50 | Peking Union Medical College HospitalOTHER | 1 | May 25, 2022 | clinicaltrials |
| NCT05322733 | Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL | unknown | Phase 2 | 25 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT05286164 | Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART | unknown | Phase 2 | 30 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Apr 15, 2022 | clinicaltrials |
| NCT04058470 | Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 140 | Huiqiang HuangOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT04246359 | Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma(RIPPLE) | unknown | Phase 2 | 52 | Huiqiang HuangOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT04514393 | Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma | unknown | Phase 2 | 33 | Huiqiang HuangOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT05093140 | Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL(CREDIT) | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 0 | Apr 7, 2022 | clinicaltrials |
| NCT05287984 | Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL(ZFCR/ZBR) | unknown | Phase 2 | 63 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05147493 | A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment | unknown | Phase 2 | 51 | Hellenic Society of HematologyOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT05298683 | A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor | unknown | Phase 2 | 108 | Hellenic Society of HematologyOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT05290337 | ZR-CHOP in DLBCL With Specific Gene Abnormality | unknown | Phase 2 | 62 | Fudan UniversityOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05200312 | A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma(ZR2-CHOP) | unknown | Phase 2 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT02481310 | Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma | unknown | Phase 1 / Phase 2 | 38 | Northwestern UniversityOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT03837873 | DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma | unknown | Phase 2 | 118 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT03629873 | Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects | unknown | Phase 2 | 69 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT05155215 | Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma | unknown | Phase 1 / Phase 2 | 68 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 0 | Dec 13, 2021 | clinicaltrials |
| NCT05150522 | B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT05143112 | Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma(CAR-T) | unknown | Phase 1 / Phase 2 | 20 | Shenzhen University General HospitalOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT05066646 | A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)(FUMANBA-1) | unknown | Phase 1 / Phase 2 | 132 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05076097 | A Study of OLR in First-line Treatment of Mantle Cell Lymphoma | unknown | Phase 2 | 29 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 11, 2021 | clinicaltrials |
| NCT05114109 | Isatuximab in Type I Cryoglobulinemia(ICE) | unknown | Phase 2 | 21 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Nov 9, 2021 | clinicaltrials |
| NCT04948788 | SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma | unknown | Phase 2 | 102 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 28, 2021 | clinicaltrials |
| NCT05049473 | Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. | unknown | Phase 2 | 100 | PETHEMA FoundationOTHER | 1 | Sep 20, 2021 | clinicaltrials |
| NCT05014100 | Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma | unknown | Phase 2 | 55 | Puyang Oilfield General HospitalOTHER | 0 | Aug 27, 2021 | clinicaltrials |
| NCT04736914 | Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma | unknown | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Aug 26, 2021 | clinicaltrials |
| NCT05021770 | Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma | unknown | Phase 1 / Phase 2 | 29 | Huiqiang HuangOTHER | 1 | Aug 26, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Oct 12, 2022source: clinicaltrials